About US
Contact us
-
InvaGen to acquire Avenue Therapeutics for $215mInvaGen Pharmaceuticals, a unit of India-based Cipla, has signed definitive agreements to buy US-based specialty pharmaceutical firm Avenue Therapeutics for a total consideration of $215m. Avenue The2018/11/15
-
Sobi to buy US rights to AstraZeneca’s Synagis drug for $1.5bnSwedish biopharmaceutical firm Swedish Orphan Biovitrum (Sobi) has signed agreements to acquire the rights to AstraZeneca’s Synagis (palivizumab) medicine in the US for an upfront payment of $1.5bn.2018/11/15
-
Nestle Health increases stake in Aimmune TherapeuticsNestlé Health Science has raised its equity stake in biopharmaceutical firm Aimmune Therapeutics to around 19% with an investment of $98m. The deal increases Nestle Health’s total investment in Aimmu2018/11/14
-
WHO finds wide differences in global antibiotics consumptionA survey by the World Health Organization (WHO) has revealed huge variations in the use of antibiotics across the world, with certain countries recording very high levels of consumption. The WHO Repo2018/11/14
-
Asterias Biotherapeutics to merge with BioTimeUS-based biotechnology firms BioTime and Asterias Biotherapeutics have entered into a definitive merger agreement to form an integrated company focussed on cell therapies. Under the terms o2018/11/13
-
Takeda sets date for shareholder EGM over acquisition of ShireJapan-based pharmaceutical company Takeda has announced 5 December as the date of its emergency general meeting (EGM) where shareholders will vote on its acquisition of UK-listed Shire for $62bn. If2018/11/13
-
AstraZeneca gets back to growth, but can it hit $40B by 2023? CEO says yes—againAstraZeneca CEO Pascal Soriot has repeatedly said his company would finally get back on the upswing in the second half of this year, and he’s put skeptics to rest with strong third-quarter numbers. No2018/11/12
-
As Novartis' other cancer launches struggle, Lutathera gets off to flying startNovartis has stumbled with a couple of its recent cancer launches, namely the complicated CAR-T rollout for Kymriah and come-from-behind Kisqali debut. But not so with Lutathera. The drug,approvedin2018/11/12
-
Themis eyes phase 3 study for chikungunya vaccine after passing midstage testThere aren't any vaccines or treatments for the painful viral infection chikungunya, but with phase 2 results announced this week, Themis hopes it's one step closer to changing that. The vaccine,2018/11/9
-
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myelomaLess than five months after posting positive top-linedata, Bristol-Myers Squibb and AbbVie have scored a new combo win for Empliciti. Tuesday, the FDAgreenlightedthe multiple myeloma immunotherapy, i2018/11/9